Compare Inovio Pharmaceuticals Inc (INO) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PPG Industries, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while PPG Industries, Inc. trades at $105.12 (market cap $23.44B). The key difference: PPG Industries, Inc. is far larger — about 208.9× Inovio Pharmaceuticals Inc's market cap, and PPG Industries, Inc. pays a 2.81% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and PPG Industries, Inc. for 68 Days on average.
| INO | PPG | |
|---|---|---|
Market Cap | $112.19M | $23.44B |
Volume | 3,201,278 | 2,064,777 |
Sector | Health | Basic Materials |
52-Week High | $2.65 | $131.56 |
52-Week Low | $0.66 | $94.34 |
Typical Hold Time | 43 Days | 68 Days |
Enterprise Value | $83.51M | $29.31B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
PPG trades at $105.08, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q2 2026 EPS miss of $2.23 vs. $2.25 expected, though Q1 2026 beat expectations. Fundamentals show a P/E of 15.13, net income margin of 9.57%, and strong cash flow from operations of $1.94B in 2025. Recent news highlights margin pressures in the Automotive Refinish segment but innovation efforts in marine coatings.
The outlook is cautiously optimistic, with a consensus price target of $130 implying 24% upside, supported by 55% analyst buy ratings. Risks include segment-specific weakness and macroeconomic headwinds, but valuation remains reasonable with solid profitability. The stock offers a dividend yield from its upcoming $0.74 payout, appealing for income-focused investors amid ongoing cost management initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
